AI Article Synopsis
- - The study evaluated the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) among Kaiser Permanente Northern California patients in the wake of the COVID-19 pandemic, involving nearly 10,000 adults.
- - An estimated 1.67% of participants reported ME/CFS-like illness, with about 14.12% of those cases occurring after a COVID-19 infection, particularly among unvaccinated individuals or those who had COVID-19 early in the pandemic.
- - Despite the findings, the overall impact of COVID-19 on increasing rates of ME/CFS-like illness appeared minimal during the study period, but those identified with the illness experienced significant impairments in multiple areas of functioning
Article Abstract
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized.
Methods: In this population-based cross-sectional study, we enrolled a stratified random sample of 9,825 adult participants in the Kaiser Permanente Northern California (KPNC) integrated health system from July to October 2022 to assess overall ME/CFS-like illness prevalence and the proportion that were identified following COVID-19 illness. We used medical record and survey data to estimate the prevalence of ME/CFS-like illness based on self-reported symptoms congruent with the 2015 Institute of Medicine ME/CFS criteria. History of COVID-19 was based on a positive SARS-CoV-2 nucleic acid amplification test or ICD-10 diagnosis code in the medical record, or self-report of prior COVID-19 on a survey.
Results: Of 2,745,374 adults in the eligible population, an estimated 45,892 (95% confidence interval [CI]: 32,869, 58,914) or 1.67% (CI 1.20%, 2.15%) had ME/CFS-like illness. Among those with ME/CFS-like illness, an estimated 14.12% (CI 3.64%, 24.6%) developed the illness after COVID-19. Among persons who had COVID-19, those with ME/CFS-like illness after COVID-19 were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021. All persons with ME/CFS-like illness had significant impairment in physical, mental, emotional, social, and occupational functioning compared to persons without ME/CFS-like illness.
Conclusions: In a large, integrated health system, 1.67% of adults had ME/CFS-like illness and 14.12% of all persons with ME/CFS-like illness developed it after COVID-19. Though COVID-19 did not substantially increase ME/CFS-like illness in the KPNC population during the study time period, ME/CFS-like illness nevertheless affects a notable portion of this population and is consistent with estimates of ME/CFS prevalence in other populations. Additional attention is needed to improve awareness, diagnosis, and treatment of ME/CFS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410243 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309810 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
A pilot cross-sectional investigation of symptom clusters and associations with patient-reported outcomes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition.
Qual Life Res
December 2024
National Centre for Neuroimmunology and Emerging Diseases, Griffith University, 1 Parklands Drive, Southport Gold Coast, Brisbane, QLD, 4222, Australia.
Article Synopsis
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post COVID-19 Condition (PCC) share similar debilitating symptoms, including fatigue and cognitive issues, impacting quality of life and functionality.
- The study involved Australian adults with ME/CFS and PCC, using self-reported questionnaires to assess symptoms and health outcomes, revealing significant differences in age and symptom associations between the two groups.
- Findings suggest that illness duration influences symptom severity, highlighting the need for clearer diagnostic criteria for PCC to better identify individuals at risk of developing chronic ME/CFS-like illnesses.
Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey.
PLoS One
September 2024
Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America.
Article Synopsis
- - The study evaluated the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) among Kaiser Permanente Northern California patients in the wake of the COVID-19 pandemic, involving nearly 10,000 adults.
- - An estimated 1.67% of participants reported ME/CFS-like illness, with about 14.12% of those cases occurring after a COVID-19 infection, particularly among unvaccinated individuals or those who had COVID-19 early in the pandemic.
- - Despite the findings, the overall impact of COVID-19 on increasing rates of ME/CFS-like illness appeared minimal during the study period, but those identified with the illness experienced significant impairments in multiple areas of functioning
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection.
JAMA Netw Open
July 2024
Division of General Internal Medicine & Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles.
Importance: Chronic symptoms reported following an infection with SARS-CoV-2, such as cognitive problems, overlap with symptoms included in the definition of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Objective: To evaluate the prevalence of ME/CFS-like illness subsequent to acute SARS-CoV-2 infection, changes in ME/CFS symptoms through 12 months of follow-up, and the association of ME/CFS symptoms with SARS-CoV-2 test results at the acute infection-like index illness.
Design, Setting, And Participants: This prospective, multisite, longitudinal cohort study (Innovative Support for Patients with SARS-CoV-2 Infections Registry [INSPIRE]) enrolled participants from December 11, 2020, to August 29, 2022.
Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID.
Int J Mol Sci
March 2023
Department of Biochemistry, School of Biomedical Sciences, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex condition arising in susceptible people, predominantly following viral infection, but also other stressful events. The susceptibility factors discussed here are both genetic and environmental although not well understood. While the dysfunctional physiology in ME/CFS is becoming clearer, understanding has been hampered by different combinations of symptoms in each affected person.
View Article and Find Full Text PDFMolecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses.
Front Neurol
May 2022
Department of Pathology, University of Otago, Dunedin, New Zealand.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease now well-documented as having arisen commonly from a viral infection, but also from other external stressors, like exposure to agricultural chemicals, other types of infection, surgery, or other severe stress events. Research has shown these events produce a systemic molecular inflammatory response and chronic immune activation and dysregulation. What has been more difficult to establish is the hierarchy of the physiological responses that give rise to the myriad of symptoms that ME/CFS patients experience, and why they do not resolve and are generally life-long.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!